查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1675766

2025 年至 2033 年肝素市場規模、佔有率、趨勢及預測（按產品、來源、給藥方式、應用、最終用戶、配銷通路和地區分類）

Heparin Market Size, Share, Trends and Forecast by Product, Source, Mode of Administration, Application, End-User, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球肝素市場規模價值為 74.6 億美元。北美目前佔據市場主導地位，到 2024 年將佔據 36% 的顯著市場佔有率。 對心血管疾病有效治療方案的需求不斷成長、主要參與者對研發活動的大量投資、眾多外科手術的日益普及以及易患慢性病的老年人口數量的大幅增加是推動市場發展的關鍵因素。

肝素 (C12H19NO20S3) 是一種廣泛使用的抗凝血劑，它是一種抑制血液凝固的物質，因此在各種醫療應用中至關重要。這種藥物來自動物組織，給患者服用可以預防靜脈、動脈和肺部的血栓。肝素主要由硫酸多醣組成，其特性包括起效迅速，並能與抗凝血酶 III 形成複合物，使凝血酶失去活性。它用於各種醫療情況，例如手術、透析以及深部靜脈栓塞和肺栓塞的治療。肝素透過增強人體的天然抗凝血反應、分解血塊並防止新血塊的形成發揮作用。

全球市場主要受對心血管疾病有效治療方案日益成長的需求所推動。同時，多種多樣且價格實惠的肝素選擇的廣泛普及也為市場提供了動力。此外，老齡人口的大幅增加，更容易罹患凝血疾病，這也成為推動市場成長的重要因素。除此之外，需要抗凝血治療的手術和侵入性手術的數量不斷增加，導致產品需求增加。有組織的醫療保健系統的實施進一步推動了市場的發展，該系統需要對血液相關疾病進行適當的管理。除此之外，導致凝血障礙的生活方式相關疾病的流行也推動了市場的發展。其他推動市場發展的因素包括快速的城市化和現代生活方式、向更積極主動的健康管理的文化轉變，以及醫療保健提供者、製藥公司和研究機構之間的廣泛合作。

肝素市場趨勢/促進因素：

慢性病數大幅增加

全球心臟病、癌症和糖尿病等慢性病的增多，使得抗凝血劑，特別是肝素的使用成為人們關注的焦點。這些慢性病常常會導致血栓和血栓形成等繼發性併發症，需要使用抗凝血劑來控制和預防這些可能致命的事件。隨著生活方式的不斷變化，久坐習慣、不良飲食習慣和其他因素導致這些慢性病的增加，從而推動了對有效的血栓管理治療的需求。此外，醫療從業人員和醫療機構正在推廣預防措施，包括對高風險患者的使用。這種抗凝血劑在治療日益普遍的疾病併發症方面的廣泛應用，成為市場擴張的基石，塑造了醫療保健的現有實踐和未來趨勢。

藥物輸送系統的技術不斷進步

技術創新已成為市場的關鍵因素。輸液幫浦、預充式注射器和標靶輸送等藥物傳遞系統的進步確保了抗凝血劑的給藥更加準確、有效。這些創新降低了用藥過量和副作用的風險，從而提高了患者的安全性和舒適度。此外，隨著醫療技術的發展，數位監控與肝素輸送的結合可以即時監測患者的反應，從而實現個人化的治療計劃和更高的治療效果。對該技術的持續研究和投入不僅改善了抗凝血劑的整體使用體驗，而且還增強了醫療保健提供者和患者之間的信任。這方面的技術與醫學的融合是一個重要的驅動力，引導市場朝著更動態、以病人為中心的方向發展。

不斷增加的監管支持和批准

市場擴張受到監管環境的顯著影響，涵蓋各個政府機構、國際組織和醫療保健機構。嚴格的監管環境確保肝素產品符合品質、安全和功效標準。這種審查涵蓋每個階段，從研發階段到上市後監管。新肝素配方和應用的快速核准流程，以及明確的指導方針和支持政策，有助於促進藥物的可用性和正確使用。此外，監管支持通常也延伸到研究的財政誘因、政府與製藥公司之間的合作以及針對血栓疾病的公眾宣傳活動。透過創造一個平衡安全與創新的環境，監管支持成為肝素市場強勁成長、建立信任和確保有需要的患者獲得最好的照護的重要支柱。

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球肝素市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場區隔：按產品
  • 市場區隔：依來源
  • 市場區隔：依管理模式
  • 市場區隔：按應用
  • 市場區隔：按最終用戶
  • 市場區隔：按配銷通路
  • 市場分佈：按地區
  • 市場預測

第6章：市場區隔：依產品

  • 普通肝素
  • 低分子量肝素 (LMWH)
  • 超低分子量肝素 (ULMWH)

第7章：市場區隔：依來源

  • 牛
  • 豬

第 8 章：市場區隔：依管理模式

  • 口服
  • 腸外

第 9 章：市場區隔：按應用

  • 心房顫動和心臟病
  • 中風
  • 深部靜脈血栓形成 (DVT)
  • 肺栓塞（PE）
  • 其他

第 10 章：市場區隔：依最終用戶

  • 醫院
  • 診所
  • 家庭護理設置
  • 門診手術中心
  • 其他

第 11 章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 藥局
  • 線上商店
  • 其他

第 12 章：市場區隔：按地區

  • 歐洲
  • 北美洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第 13 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第 17 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • GlaxoSmithKline Plc
    • Shenzhen Hepalink Pharmaceutical Co., Ltd
    • Pfizer Inc.
    • LEO Pharma A/S
    • Sanofi SA
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Aspen Holdings
    • Baxter International Inc.
    • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • Sandoz International GmbH
    • Opocrin SpA
    • Sichuan Deebio Pharmaceutical Co., Ltd.
    • Dongying Tiandong Pharmaceutical Co., Ltd.
Product Code: SR112025A1564

The global heparin market size was valued at USD 7.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 9.02 Billion by 2033, exhibiting a CAGR of 2.12% during 2025-2033. North America currently dominates the market, holding a significant market share of 36% in 2024. The rising need for effective treatment options for cardiovascular diseases, substantial investments in R&D activities by the key players, the growing prevalence of numerous surgical procedures, and the considerable rise in the number of geriatric population that is susceptible to chronic diseases are the key factors bolstering the market.

Heparin (C12H19NO20S3) is a widely used anticoagulant, a substance that inhibits blood clotting, making it essential in various medical applications. Sourced from animal tissues, this medication is administered to patients to prevent blood clots in veins, arteries, and lungs. Comprising mainly of sulfated polysaccharides, the properties of heparin include a rapid onset of action and the ability to form a complex with antithrombin III, which inactivates clotting enzymes. It's used in various medical situations such as during surgeries, dialysis, and in the treatment of deep vein thrombosis and pulmonary embolisms. Heparin works by enhancing the body's natural anticoagulant response, breaking down clots, and preventing the formation of new ones.

The global market is primarily driven by the increasing need for effective treatment options for cardiovascular diseases. In line with this, the widespread availability of varied and affordable heparin options is also providing an impetus to the market. Moreover, the considerable rise in the aging population, more susceptible to clotting disorders, is acting as a significant growth-inducing factor for the market. In addition to this, the growing number of surgeries and invasive procedures requiring anticoagulation therapy is resulting in higher product demand. The market is further driven by the implementation of organized healthcare systems that necessitate the proper management of blood-related conditions. Apart from this, the prevalence of lifestyle-related diseases that may lead to clotting disorders is propelling the market. Some of the other factors contributing to the market include rapid urbanization and modern lifestyles, the cultural shift towards more proactive health management, and extensive collaboration between healthcare providers, pharmaceutical companies, and research institutions.

Heparin Market Trends/Drivers:

Considerable rise in the number of chronic conditions

The global rise in chronic conditions such as heart disease, cancer, and diabetes has brought the use of anticoagulants, particularly heparin, into sharp focus. These chronic conditions often lead to secondary complications like blood clots and thrombosis, requiring the administration of anticoagulants to manage and prevent these potentially fatal occurrences. As lifestyles continue to evolve, sedentary habits, poor diet, and other factors are contributing to an increase in these chronic conditions, thereby pushing the demand for effective clot management treatments. Furthermore, healthcare practitioners and medical organizations are promoting preventive measures, including use in at-risk patients. This wide-ranging applications of this anticoagulant in managing complications from an increasingly prevalent group of diseases is serving as a cornerstone in the expansion of the market, shaping both current practices and future trends in healthcare.

Continual technological advancements in drug delivery systems

Technological innovation has become a pivotal factor in the market. The advancement in drug delivery systems, such as infusion pumps, prefilled syringes, and targeted delivery, ensures that the anticoagulant can be administered more accurately and effectively. These innovations reduce the risk of overdosage and side effects, thereby enhancing patient safety and comfort. Additionally, as medical technology evolves, the integration of digital monitoring with heparin delivery allows for real-time monitoring of patient response, enabling personalized treatment plans and greater therapeutic efficacy. The continuous research and investment in this technology not only improve the overall usage experience of anticoagulants but also foster trust among healthcare providers and patients. The convergence of technology and medicine in this aspect is a significant driving force, steering the market towards a more dynamic and patient-centric direction.

Growing regulatory support and approvals

The market expansion is significantly impacted by the regulatory landscape, encompassing various government bodies, international organizations, and healthcare authorities. The stringent regulatory environment ensures that heparin products meet quality, safety, and efficacy standards. This scrutiny extends to every stage, from the research and development phase to post-market surveillance. Rapid approval processes for new Heparin formulations and applications, alongside clear guidelines and supportive policies, help facilitate the drug's availability and proper usage. Furthermore, the regulatory support often extends to financial incentives for research, collaboration between governments and pharmaceutical companies, and public awareness campaigns about blood clot disorders. By cultivating an environment that balances safety with innovation, the regulatory support serves as a key pillar in the robust growth of the Heparin market, fostering trust, and ensuring that the best possible care reaches patients in need.

Heparin Industry Segmentation:

Breakup by Product:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

Low molecular weight heparin (LMWH) represents the largest market segment

The growing preference for low molecular weight heparin (LMWH) can be attributed to its enhanced bioavailability and prolonged action compared to the unfractionated variant. LMWH offers a more predictable dose-response relationship, reducing the need for frequent monitoring and dose adjustments. Its lower risk of causing heparin-induced thrombocytopenia (HIT) contributes to its favorability in both prophylactic and therapeutic settings. Additionally, LMWH's ease of subcutaneous administration and potential for outpatient care further promote its adoption, aligning with the trend towards patient-centric healthcare.

On the other hand, the unfractionated heparin and ultra-low molecular weight heparin (ULMWH) segments of the market are driven by several factors. These factors include their clinical efficacy in preventing and treating thrombotic conditions, their diverse applications in addressing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, and the influence of physician preferences based on patient profiles and medical history.

Breakup by Source:

  • Bovine
  • Porcine

Porcine accounts for the majority of the market share

The utilization of porcine mucosal tissues as the primary product source is driven by the high concentration of precursors in these tissues. Porcine source remains integral to the heparin production process due to its reliability, scalability, and cost-effectiveness. However, the industry's ongoing exploration of alternative sources, driven by concerns over availability and ethical considerations, underscores the importance of diversifying raw material options to ensure a stable supply chain for this critical anticoagulant.

On the other hand, the use of heparin sourced from bovine origins has been historically prominent in medical applications due to its availability and established track record. Also, continual advances in purification processes have addressed concerns related to potential contaminants and allergenic reactions associated with bovine-sourced anticoagulants, which is impelling the segment.

Breakup by Mode of Administration:

  • Oral
  • Parenteral

Oral represents the largest market segment

The development of oral formulations for anticoagulants marks a significant advancement in patient care. The shift from injectable to oral administration stems from the desire to enhance patient compliance, reduce the burden of injections, and facilitate long-term therapy. However, the challenge lies in achieving consistent bioavailability and maintaining predictable anticoagulation effects with oral formulations. Extensive research and clinical trials are being conducted to refine oral anticoagulant drugs, aiming to strike a balance between efficacy, safety, and convenience.

On the other hand, the parenteral mode of administration, involving injections, offers immediate effects that are particularly suitable for acute situations such as stroke and thrombotic events. This mode of administration ensures predictable dosing, which enhances patient safety and treatment efficacy.

Breakup by Application:

  • Atrial Fibrillation & Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Atrial fibrillation and heart attacks account for the majority of the market share

Atrial fibrillation and heart attacks are pivotal drivers of the demand for various anticoagulants. The increased incidence of these conditions underscores the critical role of timely and effective anticoagulation in preventing thromboembolic events. Atrial fibrillation, characterized by irregular heart rhythms, necessitates ongoing anticoagulant therapy to prevent blood clot formation and potential stroke. Meanwhile, in the context of heart attacks, the product's role as an adjunctive therapy complements other interventions to prevent further clotting and optimize patient outcomes.

On the other hand, the rising prevalence of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) drives the demand for effective anticoagulation therapies. The aging global population contributes to a higher incidence of these conditions, emphasizing the need for suitable treatment options.

Breakup by End-User:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
  • Others

Hospitals represent the largest market segment

Hospitals serve as central hubs for patient care, where the use of heparin spans from surgical procedures to the treatment of thrombotic events for preventing blood clot formation. Hospitals' high patient throughput and critical nature of care emphasize the need for accessible and effective anticoagulation options. As healthcare facilities continue to evolve, optimizing product utilization and management within hospital protocols contributes to patient safety and overall quality of care.

On the other hand, the growing product applications across clinics, homecare settings, and ambulatory surgical centers reflects its versatility in catering to different patient care environments. This is especially convenient for patients, as it allows effective treatment in home-based or ambulatory settings.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores
  • Others

Hospital pharmacies account for the majority of the market share

Hospital pharmacies play a pivotal role in the anticoagulant distribution and management within healthcare institutions. Their efficient procurement, storage, and dispensing of pharmaceuticals impact the product availability for clinicians. Additionally, hospital pharmacies facilitate communication between healthcare providers and manufacturers, ensuring timely restocking and adherence to quality standards. An effectively managed distribution channel contributes to seamless patient care and supports hospital staff in delivering appropriate therapies in a timely manner.

On the other hand, the easy product accessibility in retail pharmacies, drug stores, and online stores ensures wider patient access to necessary anticoagulant medications. This availability caters to diverse consumer preferences, allowing some patients to conveniently obtain anticoagulants from their preferred retail or online sources.

Breakup by Region:

  • Europe
  • North America
  • Asia Pacific
  • Middle East and Africa
  • Latin America

North America exhibits a clear dominance, accounting for the largest heparin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market in the North America region is propelled by the region's high incidence of chronic diseases, notably cardiovascular disorders, deep vein thrombosis, and pulmonary embolism, fuels the demand for heparin as a vital anticoagulant and thromboprophylactic agent.

This demand is further magnified by the increasing proportion of the aging population, a demographic more prone to conditions necessitating anticoagulant treatment. The region's advanced healthcare infrastructure, coupled with the burgeoning number of surgical procedures, including cardiovascular surgeries and orthopedic interventions, fosters a significant need for heparin-based products to mitigate blood clot formation risks.

Improved awareness of thrombotic disorders and enhanced diagnostic techniques contribute to early detection and treatment, amplifying the necessity for product interventions. The stringent regulatory landscape in North America ensures the secure and effective utilization of anticoagulant drugs, including heparin, while ongoing research, collaborative endeavors, and innovations in the field continually refine product efficacy and safety profile. In summation, a dynamic interplay of demographic trends, healthcare infrastructure, medical awareness, regulatory standards, and research advancements collectively stimulate the rising demand for anticoagulant products across various medical domains.

Competitive Landscape:

The leading market players are investing significantly in R&D to develop improved formulations and delivery methods, enhancing the effectiveness and safety of heparin products. These efforts aim to address medical needs more efficiently and reduce potential side effects. To tap into new markets and diversify revenue streams, major manufacturers are expanding their geographic presence by establishing distribution networks, manufacturing facilities, and sales operations in emerging markets. Additionally, they are investing in advanced quality control measures, adherence to Good Manufacturing Practices (GMP), and transparency in their supply chains to maintain customer trust and regulatory approval. The key players are also forming strategic partnerships with research institutions, healthcare providers, and pharmaceutical companies to collectively advance heparin-based treatments.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • GlaxoSmithKline Plc
  • Shenzhen Hepalink Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Holdings
  • Baxter International Inc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Sandoz International GmbH
  • Opocrin S.p.A.
  • Sichuan Deebio Pharmaceutical Co., Ltd.
  • Dongying Tiandong Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

  • 1.How big is the heparin market?
  • 2.What is the future outlook of the heparin market?
  • 3.What are the key factors driving the heparin market?
  • 4.Which region accounts for the largest heparin market share?
  • 5.Which are the leading companies in the global heparin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Heparin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Product
  • 5.5 Market Breakup by Source
  • 5.6 Market Breakup by Mode of Administration
  • 5.7 Market Breakup by Application
  • 5.8 Market Breakup by End-User
  • 5.9 Market Breakup by Distribution Channel
  • 5.10 Market Breakup by Region
  • 5.11 Market Forecast

6 Market Breakup by Product

  • 6.1 Unfractionated Heparin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Low Molecular Weight Heparin (LMWH)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Bovine
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Porcine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Mode of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Atrial Fibrillation & Heart Attack
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stroke
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Deep Vein Thrombosis (DVT)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pulmonary Embolism (PE)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Homecare Settings
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Ambulatory Surgical Centers
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Stores
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Online Stores
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast
  • 11.5 Others
    • 11.5.1 Market Trends
    • 11.5.2 Market Forecast

12 Market Breakup by Region

  • 12.1 Europe
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 North America
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Asia Pacific
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Middle East and Africa
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Latin America
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 GlaxoSmithKline Plc
    • 17.3.2 Shenzhen Hepalink Pharmaceutical Co., Ltd
    • 17.3.3 Pfizer Inc.
    • 17.3.4 LEO Pharma A/S
    • 17.3.5 Sanofi S.A.
    • 17.3.6 Dr. Reddy's Laboratories Ltd.
    • 17.3.7 Teva Pharmaceutical Industries Ltd.
    • 17.3.8 Aspen Holdings
    • 17.3.9 Baxter International Inc.
    • 17.3.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • 17.3.11 Sandoz International GmbH
    • 17.3.12 Opocrin S.p.A.
    • 17.3.13 Sichuan Deebio Pharmaceutical Co., Ltd.
    • 17.3.14 Dongying Tiandong Pharmaceutical Co., Ltd.

List of Figures

  • Figure 1: Global: Heparin Market: Major Drivers and Challenges
  • Figure 2: Global: Heparin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Heparin Market: Breakup by Product (in %), 2024
  • Figure 4: Global: Heparin Market: Breakup by Source (in %), 2024
  • Figure 5: Global: Heparin Market: Breakup by Mode of Administration (in %), 2024
  • Figure 6: Global: Heparin Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Heparin Market: Breakup by End-User (in %), 2024
  • Figure 8: Global: Heparin Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Heparin Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Heparin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 11: Global: Heparin Industry: SWOT Analysis
  • Figure 12: Global: Heparin Industry: Value Chain Analysis
  • Figure 13: Global: Heparin Industry: Porter's Five Forces Analysis
  • Figure 14: Global: Heparin (Unfractionated) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Heparin (Unfractionated) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Heparin (Low Molecular Weight) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Heparin (Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Heparin (Ultra-Low Molecular Weight) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Heparin (Ultra-Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Heparin (Bovine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Heparin (Bovine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Heparin (Porcine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Heparin (Porcine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Heparin (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Heparin (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Heparin (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Heparin (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Heparin (Atrial Fibrillation & Heart Attack) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Heparin (Atrial Fibrillation & Heart Attack) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Heparin (Stroke) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Heparin (Stroke) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Heparin (Deep Vein Thrombosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Heparin (Deep Vein Thrombosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Heparin (Pulmonary Embolism) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Heparin (Pulmonary Embolism) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Heparin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Heparin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Heparin (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Heparin (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Heparin (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Heparin (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Heparin (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Heparin (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Heparin (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Heparin (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Heparin (Other End-Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Heparin (Other End-Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Heparin Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
  • Figure 49: Global: Heparin Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
  • Figure 50: Global: Heparin Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
  • Figure 51: Global: Heparin Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
  • Figure 52: Global: Heparin Market: Sales through Drug Stores (in Million USD), 2019 & 2024
  • Figure 53: Global: Heparin Market Forecast: Sales through Drug Stores (in Million USD), 2025-2033
  • Figure 54: Global: Heparin Market: Sales through Online Stores (in Million USD), 2019 & 2024
  • Figure 55: Global: Heparin Market Forecast: Sales through Online Stores (in Million USD), 2025-2033
  • Figure 56: Global: Heparin Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
  • Figure 57: Global: Heparin Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
  • Figure 58: Europe: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: North America: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: North America: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Asia Pacific: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Asia Pacific: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Middle East and Africa: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Middle East and Africa: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Heparin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Heparin Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Heparin Market Forecast: Breakup by Source (in Million USD), 2025-2033
  • Table 4: Global: Heparin Market Forecast: Breakup by Mode of Administration (in Million USD), 2025-2033
  • Table 5: Global: Heparin Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Heparin Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 7: Global: Heparin Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 8: Global: Heparin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Heparin Market Structure
  • Table 10: Global: Heparin Market: Key Players